Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer’s Disease

From an epidemiological and pathophysiological point of view, Alzheimer’s disease (AD) and type 2 diabetes (T2DM) should be considered 'sister' diseases. T2DM significantly increases the risk of developing AD, and the mechanisms of neuronal degeneration themselves worsen peripheral glucose...

Descripción completa

Detalles Bibliográficos
Autores principales: Colin, Ides M, Szczepanski, Lidia W, Gérard, Anne-Catherine, Elosegi, Jose-Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2023
Materias:
Diabetes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258618/
https://www.ncbi.nlm.nih.gov/pubmed/37313236
http://dx.doi.org/10.17925/EE.2023.19.1.16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258618/
https://www.ncbi.nlm.nih.gov/pubmed/37313236
http://dx.doi.org/10.17925/EE.2023.19.1.16

Ejemplares similares